In recent years, the Federal Trade Commission (FTC) has closely scrutinized "reverse payment" patent settlements in which brand-name drug manufacturers make payments to generic manufacturers. The FTC is concerned that such settlements harm consumers by delaying the market entry of... MORE>>




